KSD-101

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameKSD-101
Drug Alias NameAutologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate(Kousai Bio)KSD-101
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHematologic NeoplasmsNasopharyngeal CarcinomaLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKousai Bio Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesKousai Bio Co LtdSun Yat-Sen UniversityZhongshan Hengsai Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsNasopharyngeal CarcinomaEpstein-Barr Virus Infections
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A